PCSK9 inhibitors: Going forward and beyond

被引：1
|
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [21] Thumbs Up for PCSK9 Inhibitors
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (03): : 217 - 217
  • [22] PCSK9 inhibitors - clinical applications
    Schmidli, Robert
    AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 168 - 170
  • [23] PCSK9 Inhibitors for Familial Hypercholesterolemia
    Lenahan, Christy M.
    Harringtoon, Deedra
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2016, 12 (08): : 577 - 578
  • [24] The Evolving Future of PCSK9 Inhibitors
    Rosenson, Robert S.
    Hegele, Robert A.
    Fazio, Sergio
    Cannon, Christopher P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (03) : 314 - 329
  • [25] PCSK9 Inhibitors: The Evolving Future
    Jeswani, Bijay Mukesh
    Sharma, Shubhangi
    Rathore, Sawai Singh
    Nazir, Abubakar
    Bhatheja, Rohit
    Kapoor, Kapil
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [26] Are PCSK9 Inhibitors Cost Effective?
    Max J. Korman
    Kjetil Retterstøl
    Ivar Sønbø Kristiansen
    Torbjørn Wisløff
    PharmacoEconomics, 2018, 36 : 1031 - 1041
  • [27] Therapeutic contribution of PCSK9 inhibitors
    Millan Nunez-Cortes, Jesus
    Pedro-Botet, Juan
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 39 - 41
  • [28] EFFICACY BIOMARKER FOR PCSK9 INHIBITORS
    Laaksonen, R.
    Koistinen, K.
    Huuhilo, R.
    Tarasov, K.
    Hurme, R.
    Ekroos, K.
    Prat, A.
    Seidah, N.
    Janis, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 104 - 104
  • [29] PCSK9 inhibitors - mechanisms of action
    Page, Michael M.
    Watts, Gerald F.
    AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 164 - 167
  • [30] Cholesterol reduction with PCSK9 inhibitors
    Lambooij A.
    Huisarts en wetenschap, 2018, 61 (9) : 18 - 20
12345